Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | hexokinase, putative | 0.1162 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.1162 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.1162 | 1 | 1 |
Onchocerca volvulus | 0.1162 | 1 | 1 | |
Plasmodium vivax | hexokinase, putative | 0.1162 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.1162 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.1162 | 1 | 1 |
Echinococcus multilocularis | hexokinase | 0.1162 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 1 | 0.1162 | 1 | 0.5 |
Treponema pallidum | hexokinase (hxk) | 0.1162 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase type 2 | 0.1162 | 1 | 0.5 |
Echinococcus granulosus | hexokinase type 2 | 0.1162 | 1 | 0.5 |
Trypanosoma brucei | hexokinase, putative | 0.1162 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 2 | 0.1162 | 1 | 0.5 |
Brugia malayi | Hexokinase family protein | 0.1162 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.1162 | 1 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.1162 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.1162 | 1 | 0.5 |
Plasmodium falciparum | hexokinase | 0.1162 | 1 | 0.5 |
Onchocerca volvulus | 0.1162 | 1 | 1 | |
Onchocerca volvulus | 0.1162 | 1 | 1 | |
Echinococcus granulosus | hexokinase | 0.1162 | 1 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.1162 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.1162 | 1 | 0.5 |
Schistosoma mansoni | hexokinase | 0.1162 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.1162 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0792 | 0.1468 | 0.1468 |
Toxoplasma gondii | hexokinase | 0.1162 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.1162 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.1162 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.